Fraudulent Medicines

Fraudulent medicines are products that intentionally or negligently fail to meet regulatory standards but are deceptively represented as compliant. This concept shifts focus from traditional 'counterfeiting' (often trademark infringement) to the 'fraud' inherent in the product's quality, regardless of the manufacturer's legitimacy. Within a risk management framework like ISO 31000, it represents a severe operational and compliance risk. It violates the core principles of Good Manufacturing Practice (GMP), which ensures drug quality and safety. Under regulations such as Taiwan's Pharmaceutical Affairs Act, drugs not conforming to approved specifications are deemed 'substandard,' with intentional distribution incurring criminal liability. Thus, it is a legal violation rooted in fraudulent intent, posing a direct threat to public health.

Preventing fraudulent medicines in enterprise risk management requires a multi-layered control strategy. Step 1: Implement rigorous supply chain due diligence based on Good Distribution Practices (GDP), including stringent supplier qualification, on-site audits, and continuous monitoring. Step 2: Strengthen the internal Quality Management System (QMS) by strictly adhering to Good Manufacturing Practice (GMP), covering mandatory testing of raw materials and comprehensive batch release testing for final products. Step 3: Establish end-to-end traceability by deploying serialization and track-and-trace systems, as mandated by regulations like the U.S. DSCSA and Taiwan's traceability laws. A global pharmaceutical company implementing these measures reduced the risk of non-compliant products entering the market by over 95% and achieved a 100% pass rate in regulatory audits.

Taiwanese enterprises face three key challenges in managing fraudulent medicine risks. 1) Complex Global Supply Chains: Verifying the quality of Active Pharmaceutical Ingredients (APIs) from diverse sources is difficult. Solution: Implement a risk-based supplier management program with increased audits and incoming material testing for high-risk suppliers. 2) Evolving Regulations: Keeping pace with updates from bodies like the ICH and Taiwan FDA is resource-intensive. Solution: Establish a dedicated regulatory intelligence unit and integrate compliance into the R&D lifecycle. 3) Data Silos: Fragmented IT systems hinder end-to-end traceability. Solution: Invest in an integrated electronic traceability platform linked to ERP and QMS. The top priority should be deploying this platform within 12 months to meet regulatory deadlines and mitigate operational risks.

Winners Consulting specializes in fraudulent medicines for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact